All In Biotech

NDA 021742 · Allergan

Bystolic

Nebivolol Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Dec 17, 2007

Approved uses

2

Original approval plus efficacy supplements

Registered trials

116

24 Phase 3, 7 recruiting

FAERS reports

17,999

9,157 serious, 861 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2024.

1. INDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension BYSTOLIC is indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. BYSTOLIC may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BYSTOLIC. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the...

Mechanism: The mechanism of action of the antihypertensive response of BYSTOLIC has not been definitively established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral vascular resistance.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 19, 2010 Supplement 7 · Efficacy LetterLabel
  • Dec 17, 2007 Original approval · Type 1 - New Molecular Entity NovelReviewLetter
4 products under this application
  • BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
  • BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 2.5MG BASE · TABLET, ORAL · Prescription · TE AB
  • BYSTOLIC · NEBIVOLOL HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nebivolol" as an intervention, any sponsor and status, largest first.

All 116 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,332
  • drug ineffective1,073
  • diarrhoea1,060
  • nausea1,030
  • headache982
  • dyspnoea936
  • dizziness906
  • off label use712
  • pain660
  • asthenia622
  • blood pressure increased587
  • arthralgia539

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200510
20068
200712
200877
2009634
2010727
2011610
2012821
2013906
20141,056
20151,619
20161,982
20171,351
20181,643
20191,399
20201,160
2021840
2022917
2023681
2024628
2025539
2026373

Recalls

1 FDA enforcement reports for this application.

  • May 12, 2014 · Class II · Terminated

    Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the product's shelf life.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bystolic (Nebivolol HCl)

2024 spending

$16.5M

Beneficiaries

9,360

41,207 claims

Per beneficiary

$1,759

$5.74 per unit

View as table
YearSpending
2020$480,351,460
2021$415,408,373
2022$74,364,816
2023$23,909,158
2024$16,462,137

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 280 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.